Mental Health Weekly
March 11, 2024
Valerie A. Canady
In response to the psychological trauma inflicted by the ongoing conflict in Ukraine, Fluence, a leader in comprehensive, evidence‐based training in psychedelic therapy announced last week a collaboration with the Ukrainian Psychedelic Research Association (UPRA) and the U.S. nonprofit Health Ukraine Trauma (HUT), to provide free training in psychedelic therapy to Ukrainian psychologists and...
Med
March 8, 2024
Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle et al.
97 citations
Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, including high levels of treatment resistance in major depressive and bipolar disorder and patients with baseline suicidality and significant comorbidity....
March 6, 2024
Bill Brennan, Alex Belser
6 citations
Abstract EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person is a comprehensive guidebook for clinicians that presents a novel therapeutic framework for administering psychedelic medicines. The EMBARK model was developed in response to the growing interest in psychedelic medicines for treating mental health disorders, particularly depression, and the identified gaps...
American Journal of Therapeutics
March 1, 2024
Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al.
9 citations
BACKGROUND: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder, depression, anxiety, and traumatic brain injury....
February 26, 2024
Bruce Ecker, Robin Ticic, Laurel Hulley
It is well established that psychedelic experiences can result in potent therapeutic change when induced within a program of psychotherapy that skillfully provides preparation of mindset, an environment of accompaniment, safety, and supportiveness during the experience(s), and a subsequent process of review, reflection, and integration. The question addressed in this chapter is whether...
Canadian Journal of Occupational Therapy
February 20, 2024
Gabriella Ann Hogan, Karen Elaine Wagner, Erin Tichenor et al.
5 citations
Background. Interest in the use of psychedelics for mental health therapy is burgeoning. Qualitative research methods are increasingly used to understand patient's experiences; however, there is a lack of literature that explores psychedelic use from an occupational perspective. Purpose. To conduct a scoping review of qualitative literature on the experiences of psychedelic use for the purpose...
Journal of Psychedelic Studies
February 5, 2024
Alesha Wells, Merciana Fernandes, Lisa Reynolds
37 citations
Abstract Background and aims Scientific interest in the therapeutic potential of psychedelics has been experiencing significant growth. Understanding the perceptions of psychedelic assisted psychotherapy (PAP) among health professional, patients, and the public is essential to guide future research objectives, trial protocols, and identify any barriers to future implementation. Methods A...
British Journal of Mental Health Nursing
February 2, 2024
Leonie Milner, Annie Mithoefer
This article looks at the emerging field of psychedelic-assisted psychotherapy and the nurse's role within that – something which is currently unexplored and wholly undefined. It draws from lived experience in psychedelic-assisted psychotherapy and is co-authored by a significant contributor in this field. The aim of the article is to give nurses a brief introduction to the field of...
Frontiers in Psychiatry
February 1, 2024
Phil Wolfson, Gita Vaid
17 citations
Psychiatry is in a growth phase in which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine is the only medicine that may be legally prescribed. We hypothesize that at subanesthetic doses, ketamine produces a unique spectrum of altered states, ranging from psychoactive to deep ego-dissolving experiences, that are intrinsic to ketamine’s...
International Journal of Whole Person Care
January 29, 2024
Houman Farzin
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individuals suffering from demoralization, death anxiety, and existential distress. Psilocybin-assisted psychotherapy employs psilocybin-containing mushrooms or synthetic psilocybin grounded in indigenous traditions and within the context of a therapeutic...